Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-01-23
DOI
10.1002/jcp.29491
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MicroRNA-mediated redox regulation modulates therapy resistance in cancer cells: clinical perspectives
- (2019) Safieh Ebrahimi et al. CELLULAR ONCOLOGY
- Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
- (2019) Karin M. Knudson et al. Journal for ImmunoTherapy of Cancer
- Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
- (2019) Elizabeth I. Buchbinder et al. Journal for ImmunoTherapy of Cancer
- Tumor-associated macrophages: role in cancer development and therapeutic implications
- (2019) Arash Salmaninejad et al. CELLULAR ONCOLOGY
- Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
- (2019) Heng Sheng Sow et al. Cells
- Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
- (2019) Amy L. Shergold et al. PHARMACOLOGICAL RESEARCH
- Recent advances in the clinical development of immune checkpoint blockade therapy
- (2019) Atefeh Ghahremanloo et al. CELLULAR ONCOLOGY
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
- (2018) Michael B. Atkins et al. CLINICAL CANCER RESEARCH
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy
- (2018) Kui Li et al. JOURNAL OF DRUG TARGETING
- IL-2 and Beyond in Cancer Immunotherapy
- (2018) John M. Wrangle et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
- (2018) Nizar M. Tannir et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis
- (2018) Li Sun et al. Cell Death & Disease
- Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
- (2018) Estefanía Paula Juliá et al. Frontiers in Immunology
- Cytokines in clinical cancer immunotherapy
- (2018) Pedro Berraondo et al. BRITISH JOURNAL OF CANCER
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Combination of PD-1 blockade and RetroNectin®-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study
- (2018) Lingdi Zhao et al. Immunotherapy
- Oxidative stress in cervical cancer pathogenesis and resistance to therapy
- (2018) Safieh Ebrahimi et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors
- (2018) Romualdo Barroso-Sousa et al. Current Oncology Reports
- PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
- (2018) Neda Yaghoubi et al. BIOMEDICINE & PHARMACOTHERAPY
- Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives
- (2017) Arash Soltani et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Effector CD8 + T cell-derived interleukin-10 enhances acute liver immunopathology
- (2017) Jessica Fioravanti et al. JOURNAL OF HEPATOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance
- (2017) Bhargavi Pulluri et al. PHARMACOLOGICAL RESEARCH
- Mechanistic and pharmacologic insights on immune checkpoint inhibitors
- (2017) Randy F. Sweis et al. PHARMACOLOGICAL RESEARCH
- Cytokines in Cancer Immunotherapy
- (2017) Thomas A. Waldmann Cold Spring Harbor Perspectives in Biology
- Abstract CT134: Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma
- (2016) Alain Algazi et al. CANCER RESEARCH
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review
- (2016) M.N Joshi et al. CLINICAL ENDOCRINOLOGY
- Interleukin 15: A key cytokine for immunotherapy
- (2016) Manoj Patidar et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
- (2016) Aung Naing et al. JOURNAL OF CLINICAL ONCOLOGY
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- IL-15Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists
- (2016) Mélanie Desbois et al. JOURNAL OF IMMUNOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer
- (2016) Congqi Dai et al. Oncotarget
- Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
- (2015) B Homet Moreno et al. BRITISH JOURNAL OF CANCER
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
- (2015) Yago Pico de Coaña et al. TRENDS IN MOLECULAR MEDICINE
- Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12
- (2015) Erica N Bozeman et al. Human Vaccines & Immunotherapeutics
- Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
- (2015) José I. Quetglas et al. Cancer Immunology Research
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
- (2015) Naiyer Rizvi et al. Journal for ImmunoTherapy of Cancer
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
- (2015) Robert D. Leone et al. Computational and Structural Biotechnology Journal
- IL-12 Regulates B7-H1 Expression in Ovarian Cancer-associated Macrophages by Effects on NF-κB Signalling
- (2014) Hai-Yu Xiong et al. Asian Pacific Journal of Cancer Prevention
- Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
- (2014) George C. Prendergast et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Interleukin 12: still a promising candidate for tumor immunotherapy?
- (2014) Witold Lasek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Interferons: Success in anti-viral immunotherapy
- (2014) Fan-ching Lin et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
- (2014) G. K. Philips et al. INTERNATIONAL IMMUNOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- The Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
- (2014) A. L. Kinter et al. JOURNAL OF IMMUNOLOGY
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Novel Recombinant Human B7-H4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor Responses
- (2013) D. Dangaj et al. CANCER RESEARCH
- PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells
- (2013) Erin E. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of Cytokines and Chemokines in the Cancer Immunotherapy
- (2013) Amedeo Amedei et al. Recent Patents on Anti-Cancer Drug Discovery
- Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors
- (2012) R Omori et al. CANCER GENE THERAPY
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN- Inducible Chemokines
- (2012) W. Peng et al. CANCER RESEARCH
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
- (2012) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- IFN- in the Treatment of Melanoma
- (2012) A. A. Tarhini et al. JOURNAL OF IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
- (2011) John B. Mumm et al. CANCER CELL
- PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
- (2011) Paola Milla et al. CURRENT DRUG METABOLISM
- Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway
- (2011) Jiao Chen et al. IMMUNOBIOLOGY
- Immunomodulatory cytokines as therapeutic agents for melanoma
- (2011) Courtney Nicholas et al. Immunotherapy
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Cytokines in Cancer Immunotherapy
- (2011) Sylvia Lee et al. Cancers
- Novel Gamma-Chain Cytokines as Candidate Immune Modulators in Immune Therapies for Cancer
- (2010) Natasha M. Fewkes et al. CANCER JOURNAL
- Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial
- (2010) H. Schmidt et al. CLINICAL CANCER RESEARCH
- Features of responding T cells in cancer and chronic infection
- (2010) Peter S Kim et al. CURRENT OPINION IN IMMUNOLOGY
- BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination
- (2010) Laurent Derré et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival
- (2010) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice
- (2009) Paula Kolar et al. ARTHRITIS AND RHEUMATISM
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
- (2009) H. Harlin et al. CANCER RESEARCH
- Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
- (2009) Pedro Berraondo et al. CURRENT GENE THERAPY
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma
- (2008) Jacob A. Klapper et al. CANCER
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- Cytokine Signaling Modules in Inflammatory Responses
- (2008) John J. O'Shea et al. IMMUNITY
- Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity
- (2007) Rosanne Spolski et al. Annual Review of Immunology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started